NCT00095381View on ClinicalTrials.gov

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

December 31, 2007

Conditions
Leukemia, T-Cell
Interventions
DRUG

forodesine hydrochloride (BCX-1777)

Trial Locations (24)

10021

Weil Medical College of Cornell University, New York

New York

10467

The Bronx

13210

Syracuse

24211

Abingdon

29303

Spartanburg

30322

Atlanta

32611

Gainesville

34461

Lecanto

48202

Detroit

60611

Chicago

60637

Chicago

63110

St Louis

65401

Rolla

66160

Kansas City

68198

Omaha

70118

New Orleans

77030

Houston

78701

Austin

80262

Denver

90024

Los Angeles

94304

Palo Alto

07601

Hackensack

GE-380079

Tbilisi

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY